QYTOVRA Trademark

Trademark Overview

On Thursday, June 2, 2022, a trademark application was filed for QYTOVRA with the United States Patent and Trademark Office. The USPTO has given the QYTOVRA trademark a serial number of 79344475. The federal status of this trademark filing is REGISTERED as of Tuesday, March 5, 2024. This trademark is owned by Dimerix Bioscience Pty Ltd. The QYTOVRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of kidney disease including focal segmental glomerulosclerosis and diabetic kidney disease
qytovra

General Information

Serial Number79344475
Word MarkQYTOVRA
Filing DateThursday, June 2, 2022
Status700 - REGISTERED
Status DateTuesday, March 5, 2024
Registration Number7318061
Registration DateTuesday, March 5, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 19, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of kidney disease including focal segmental glomerulosclerosis and diabetic kidney disease
Translation of Words in MarkThe wording QYTOVRA has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 13, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDimerix Bioscience Pty Ltd
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressAU
Party NameDimerix Bioscience Pty Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressAU
Party NameDimerix Bioscience Pty Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events

Event DateEvent Description
Tuesday, July 12, 2022LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, July 7, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Wednesday, July 13, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 19, 2022APPLICATION FILING RECEIPT MAILED
Monday, March 20, 2023ASSIGNED TO EXAMINER
Monday, March 20, 2023NON-FINAL ACTION WRITTEN
Tuesday, March 21, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, May 9, 2023REFUSAL PROCESSED BY MPU
Tuesday, May 9, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, May 31, 2023REFUSAL PROCESSED BY IB
Monday, November 6, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 6, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 6, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 9, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 29, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, December 13, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, December 19, 2023NOTIFICATION PROCESSED BY IB
Wednesday, November 29, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, December 13, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, December 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 19, 2023PUBLISHED FOR OPPOSITION
Tuesday, January 2, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, March 5, 2024REGISTERED-PRINCIPAL REGISTER
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, August 15, 2025NEW REPRESENTATIVE AT IB RECEIVED
Thursday, June 6, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 5, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

qytovra kidney disease segmental glomerulosclerosis diabetic focal including preparations pharmaceutical treatment